PD 181461
Alternative Names: PD181461Latest Information Update: 04 Aug 2009
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Aug 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
- 22 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)